PTAB challenges

Proceedings overview

There are no recorded AIA trial proceedings directly challenging US Patent 7,670,612 in the USPTO Open Data Portal as of the most recent ingest. However, a closely related patent, US 8,361,497, which is a continuation of US 7,670,612, was subject to an inter partes review (IPR) proceeding (IPR2013-00331) where all challenged claims were ultimately canceled. This outcome for the continuation patent provides significant defensive value for a defendant facing assertion of US 7,670,612, as the underlying technology and prior art are highly likely to overlap.

IPR2013-00331 — Capsugel Belgium NV v. Innercap Technologies, Inc.

• Type: Inter Partes Review
• Filed: June 6, 2013
• Status: Claims invalidated. An adverse judgment was entered against the patent owner, Innercap Technologies, Inc., resulting in the cancellation of all challenged claims of the patent-in-suit, U.S. Patent No. 8,361,497.
• Judge panel: Information not publicly available in provided search results.
• Petition grounds: Capsugel challenged all 26 issued claims of U.S. Patent No. 8,361,497. The specific prior art and statutory bases (§ 102 / § 103 / § 112) for the challenge are not detailed in the provided search results but typically involve obviousness and/or anticipation.
• Institution decision: The IPR was instituted on all challenged claims, as indicated by the subsequent adverse judgment cancelling those claims.
• Final Written Decision (if issued): An adverse judgment was entered against Innercap Technologies, Inc., leading to the cancellation of all 26 challenged claims of U.S. Patent No. 8,361,497. The specific reasoning for the cancellation is not detailed in the provided search results but implies the PTAB found the claims unpatentable based on the petition's arguments.
• Settlement / termination: The proceeding resulted in an adverse judgment and cancellation of claims, rather than a settlement.
• Appeal: Information regarding an appeal of IPR2013-00331 to the Federal Circuit is not explicitly detailed in the provided search results. While general information about IPR appeals is available, specific mention of this particular IPR's appeal status is absent.
• Defensive value: This proceeding is highly significant for anyone facing assertion of US Patent 7,670,612. As US 8,361,497 is a continuation of the '612 patent, the cancellation of all 26 claims in the IPR suggests that the underlying inventive concept, as claimed, was found unpatentable. This indicates a high likelihood that similar or broader claims in the parent US 7,670,612 would also be vulnerable to invalidation if challenged, particularly if based on the same or similar prior art.

Strategic summary

Currently, no claims of US Patent 7,670,612 have been directly challenged or canceled in any AIA trial proceeding at the PTAB. Therefore, all claims of US 7,670,612 are technically "untested" by IPR, PGR, or CBM.

However, the complete cancellation of all 26 challenged claims of US Patent 8,361,497 in IPR2013-00331 is a critical piece of information. Since US 8,361,497 is a continuation of US 7,670,612, it is expected to share substantial overlap in scope and inventiveness with its parent patent. The success of the petitioner, Capsugel Belgium NV, in invalidating all claims of the continuation patent suggests a strong possibility that similar prior art and arguments could be effectively deployed against US 7,670,612. The specific claims of US 7,670,612 are thus highly vulnerable to future challenges, especially if they are substantially similar to the claims that were canceled in IPR2013-00331.

The estoppel landscape from IPR2013-00331 would apply directly to Capsugel Belgium NV and its privies regarding US Patent 8,361,497. However, this estoppel does not directly bar other potential petitioners from challenging US Patent 7,670,612, as it is a different patent. The prior art used in IPR2013-00331 against US 8,361,497 would be highly relevant and likely still available for use against US 7,670,612. There is no information in the provided search results to indicate a pattern of multiple IPR filings by the same petitioner on this patent family or any aggressive pursuit of PTAB appeals by the patent owner concerning IPR2013-00331 specifically.

Recommended next steps

Given the absence of direct PTAB activity on US Patent 7,670,612, a defendant currently facing assertion of this patent should consider initiating an AIA trial proceeding, most likely an Inter Partes Review (IPR), against US 7,670,612. The successful invalidation of all claims of its continuation patent, US 8,361,497, in IPR2013-00331 provides a strong indication of potential vulnerability.

It is recommended to:

• Obtain the Final Written Decision for IPR2013-00331 to thoroughly understand the PTAB's reasoning and the specific prior art and grounds used to cancel the claims of US 8,361,497. This will be crucial for informing any new IPR petition against US 7,670,612. While the full decision is not provided here, information suggests it resulted in the cancellation of all 26 challenged claims.
• Analyze the claims of US 7,670,612 in light of the prior art cited in IPR2013-00331 and the "Prior art" section of this analysis. The strong prior art already identified (e.g., U.S. Patent 6,482,434 (Lledo), U.S. Patent 6,214,376 (De-Vriendt)) appears highly relevant and may form the basis of a new challenge.
• Assess the legal and factual overlap between the claims of US 7,670,612 and the canceled claims of US 8,361,497 to formulate the strongest possible obviousness and/or anticipation arguments for a new petition.
• Be aware that the patent expires on June 11, 2026. Any new PTAB proceeding would need to be filed very quickly given this approaching expiration date, and the strategic value of such a filing should be carefully considered against the remaining patent term.